论文部分内容阅读
阿德福韦(ADV)为核苷类药物,ADV-dpv(Adefovir Dipivoxil)即ADV的前体,为一亲脂性口服制剂。在前临床及Ⅱ期临床研究中,ADV-dpv显示有效的抗HBV活性,对拉米夫定耐药株亦有治疗作用。
Adefovir (ADV) is a nucleoside drug and ADV-dpv (Adefovir Dipivoxil), a precursor of ADV, is a lipophilic oral formulation. ADV-dpv showed potent anti-HBV activity in pre-clinical and phase II clinical studies and also had therapeutic effects on lamivudine-resistant strains.